Generate Biomedicines
GENB
13.57
-0.23
-1.67%
Generate Biomedicines
US · GENB
#2875 by market cap
Listed 2026
13.57
-0.23
-1.67%
Live - 5344 symbols - heartbeat 373s ago
· 2026-10-08 08:20
Pre-market
13.57
0.00%
After-hours
13.57
0.00%
Overnight
13.71
+1.03%
- Market cap
- 1.74B
- P/E (TTM)i
- -6.48
- P/Bi
- 3.82
- EPSi
- -1.96
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on GENB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 77.94% -0.41pp
- Institutions
- 101 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund53.95%
Mutual Fund15.96%
Hedge Fund5.21%
Individual/Insider4.07%
Sovereign Wealth Fund1.63%
Endowment Fund0.87%
Public Company0.26%
Other17.98%
Top holders as of 2026-06-30
Flagship Pioneering, Inc
48.83% · 62.67M sh
FMR
4.07% · 5.22M sh
Capital Research
3.28% · 4.22M sh
Braidwell LP
2.56% · 3.28M sh
Michael Nally
2.25% · 2.89M sh
T. Rowe Price Group, Inc.
1.68% · 2.16M sh
Norges Bank Investment Management
1.63% · 2.09M sh
Arch Venture Partners, L.P.
1.51% · 1.94M sh
HarbourVest Partners, LLC
1.34% · 1.72M sh
BlackRock
1.29% · 1.66M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
42 filings tracked · 19 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Flagship Pioneering, Inc | -- | 48.83% |
| Michael Nally | Chief Executive Officer | 2.25% |
| Stéphane Bancel | Independent Director | 0.92% |
| Gevorg Grigoryan | Chief Technology Officer | 0.51% |
| Frances Arnold | Independent Director | 0.36% |
| Noubar Afeyan | Co-founder & Independent Chair of the Board | 0.02% |
| Jane Mendillo | Independent Director | 0.00% |
| Jason Silvers | President, CFO & Treasurer | 0.00% |
| Beth Grous | Chief Human Resources Officer | 0.00% |
| Paul Parker | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Frances Arnold | Independent Director | Intent to Sell (Form 144) | -32,210 | $16.16 |
| 2026-08-31 | Frances Arnold | Independent Director | Automatic Disposition | -1,000 | $16.00 |
| 2026-03-03 | Michael Nally | Chief Executive Officer | Open Market Acquisition | +20,000 | $12.00 |
| 2026-03-01 | Jane Mendillo | Independent Director | Private Acquisition | +1,500 | $16.00 |
| 2026-03-01 | Stéphane Bancel | Independent Director | Derivative Exercise and Retained | +724,160 | -- |
| 2026-03-01 | Michael Nally | Chief Executive Officer | Derivative Exercise and Retained | +658,327 | -- |
| 2026-03-01 | Beth Grous | Chief Human Resources Officer | Private Acquisition | +300 | $16.00 |
| 2026-03-01 | Jason Silvers | President, CFO & Treasurer | Private Acquisition | +2,000 | $16.00 |
| 2026-02-25 | Flagship Pioneering, Inc | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Noubar Afeyan | Co-founder & Independent Chair of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Paul Parker | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Paul Parker | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Marsha Fanucci | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Marsha Fanucci | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Nancy Simonian | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Nancy Simonian | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Frances Arnold | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Frances Arnold | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Jane Mendillo | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Jane Mendillo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:20:40 · For reference only, not investment advice and not tailored to your situation.